Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single intra-articular JTA-004 in symptomatic knee osteoarthritis
2019-000796-16Phase 3Completed
- Sponsor
- BioSenic
- Start
- Dec 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of JTA-004 in knee osteoarthritis (OA) (3 arms), sponsored by BioSenic. Primary endpoint: Primary: Change in knee pain at Month 3 (WOMAC VA3.1 pain subscale A). Started Dec 2019; status: completed.
02
Drugs
JTA-004
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2019-000796-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000796-16.